1. Home
  2. MTEX vs KPRX Comparison

MTEX vs KPRX Comparison

Compare MTEX & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mannatech Incorporated

MTEX

Mannatech Incorporated

HOLD

Current Price

$6.97

Market Cap

10.0M

Sector

Health Care

ML Signal

HOLD

Logo Kiora Pharmaceuticals Inc.

KPRX

Kiora Pharmaceuticals Inc.

HOLD

Current Price

$2.58

Market Cap

11.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MTEX
KPRX
Founded
1993
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.0M
11.7M
IPO Year
1998
2014

Fundamental Metrics

Financial Performance
Metric
MTEX
KPRX
Price
$6.97
$2.58
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$10.00
AVG Volume (30 Days)
9.0K
14.5K
Earning Date
04-15-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
1.02
N/A
Revenue
$108,038,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$6.21
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.80
$1.76
52 Week High
$12.45
$2.95

Technical Indicators

Market Signals
Indicator
MTEX
KPRX
Relative Strength Index (RSI) 65.05 55.03
Support Level $6.94 $2.44
Resistance Level $7.68 $2.68
Average True Range (ATR) 0.52 0.11
MACD 0.09 0.00
Stochastic Oscillator 93.64 66.67

Price Performance

Historical Comparison
MTEX
KPRX

About MTEX Mannatech Incorporated

Mannatech Inc is a wellness solution provider. The company develops and sells nutritional supplements, topical and skin care and anti-aging products, and weight-management products that target optimal health and wellness. Mannatech sells products in three regions: the Americas (the United States, Canada, and Mexico); Europe/the Middle East/Africa (EMEA) (Austria, the Czech Republic, Denmark, Estonia, Finland, Germany, the Republic of Ireland, Namibia, the Netherlands, Norway, South Africa, Spain, Sweden, and the United Kingdom); and Asia/Pacific (Australia, Japan, New Zealand, the Republic of Korea, Singapore, Taiwan, Hong Kong, and China). Mannatech generates the majority of its revenue from the Americas.

About KPRX Kiora Pharmaceuticals Inc.

Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.

Share on Social Networks: